Page last updated: 2024-10-26

domperidone and Chronic Progressive Multiple Sclerosis

domperidone has been researched along with Chronic Progressive Multiple Sclerosis in 2 studies

Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.

Research Excerpts

ExcerptRelevanceReference
"Domperidone treatment was reasonably well tolerated, but adverse events occurred in 84% and serious adverse events in 15% of patients."3.01Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial. ( Cerchiaro, G; Cutter, GR; Kaur, S; Kim, J; Koch, MW; Metz, LM; Sage, K; Yong, VW, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Koch, MW1
Sage, K1
Kaur, S1
Kim, J1
Cerchiaro, G1
Yong, VW1
Cutter, GR1
Metz, LM1
Fox, RJ1
Kryscio, RJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)[NCT02308137]Phase 264 participants (Actual)Interventional2015-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for domperidone and Chronic Progressive Multiple Sclerosis

ArticleYear
Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology, 2021, 05-04, Volume: 96, Issue:18

    Topics: Adult; Domperidone; Dopamine Antagonists; Drug Repositioning; Female; Humans; Male; Medical Futility

2021

Other Studies

1 other study available for domperidone and Chronic Progressive Multiple Sclerosis

ArticleYear
A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology, 2021, 05-04, Volume: 96, Issue:18

    Topics: Domperidone; Humans; Medical Futility; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive

2021